Brief: An2 Therapeutics Announces Extension Of Funding For Tuberculosis Research Collaboration With Gsk
28/09/2026 12:01
BRIEF-An2 Therapeutics Announces Extension Of Funding For Tuberculosis Research Collaboration With Gsk Sept 28 (Reuters) - AN2 Therapeutics Inc ANTX.O:
AN2 THERAPEUTICS ANNOUNCES EXTENSION OF FUNDING FOR TUBERCULOSIS RESEARCH COLLABORATION WITH GSK
AN2 THERAPEUTICS - GATES FOUNDATION FUNDING SUPPORTS ADVANCEMENT OF BORON-BASED LEURS INHIBITORS FOR TB TREATMENT
Source text: ID:nBw7bC52Ca
Further company coverage: ANTX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on AN2 Therapeutics
See all newsBrief: AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(C)(4)
Brief: An2 Therapeutics Announces Extension Of Funding For Tuberculosis Research Collaboration With Gsk
AN2 Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
AN2 Therapeutics Q2 net loss widens on higher R&D costs
AN2 Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview